How Can We Help You?


Quick Info:

Find a Doctor Specialties (800) 213-3284

Go To Home PageBack

Solid Tumors

Select Clinical Trial

Protocol Number: Mirati Krystal MRTX849

Protocol Title: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Eligibility: Men or women, ages 18 and older, diagnosed with advanced cancer, which has a KRAS G12C mutation. 

Contact Information: (910) 715-2200



Protocol Number: EAY131/MATCH

Protocol Title: Molecular Analysis for Therapy Choice (MATCH)

Eligibility: Men or women, ages 18 and older whose cancer has not responded to conventional treatment or whose cancer does not have a known effective treatment. Patients/treating physician must have received notification of actionable mutation of interest(aMOI) following genetic testing of tumor at an accepted outside laboratory such as Foundation One, Caris, etc.

Contact Information: (910) 715-2200


Protocol Number: Seattle Genetics SGNLVA-005; NCT04032704

Protocol Title: Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

Eligibility: Men and women age 18 and older diagnosed with metastatic lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, gastric, gastroesophageal junction (GEJ) adenocarcinoma, Castrate Resistant Prostate cancer, or Melanoma who have progressed following their first line of therapy.

Contact Information: (910) 715-2200

Clara McLean House
Make a Donation
News & Events